4D-150 IVT (3E10 vg/eye)

BIOLOGICAL2 trials

Sponsors

4D Molecular Therapeutics

Conditions

Macular Neovascularization Secondary to Age-Related Macular DegenerationNeovascular Age-Related Macular Degeneration (nAMD)

Phase 3

4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

Active, not recruitingNCT06864988

4D Molecular TherapeuticsMacular Neovascularization Secondary to Age-Related Macular Degeneration

Start: 2025-03-03End: 2028-06-01Target: 480Updated: 2026-06-01

Single Intravitreal (IVT) Injection of 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration

RecruitingNCT07064759

4D Molecular TherapeuticsNeovascular Age-Related Macular Degeneration (nAMD)

Start: 2025-07-22End: 2029-02-01Target: 480Updated: 2026-04-16